Trial Profile
A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Cisplatin; Cytarabine; Dexamethasone
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 08 Jan 2019 Status changed from recruiting to completed.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 26 Oct 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.